Objective Markers for early identification of progressive interstitial lung disease (ILD) in systemic sclerosis (SSc) are in demand. Chemokine CCL18, which has been linked to pulmonary inflammation, ...is an interesting candidate, but data have not been consistent. We aimed to assess CCL18 levels in a large, prospective, unselected SSc cohort with longitudinal, paired data sets on pulmonary function and lung fibrosis. Methods Sera from the Oslo University Hospital SSc cohort (n = 298) and healthy control subjects (n = 100) were analyzed for CCL18 by enzyme immunoassay. High CCL18 (>53 ng/mL) was defined using the mean value plus 2 SD in sera obtained from healthy control subjects as the cutoff. Results High serum CCL18 was identified in 35% (105 of 298). Annual decline in FVC differed significantly between high and low CCL18 subsets (13.3% and 4.7%; P = .016), as did the annual progression rate of lung fibrosis (0.9% SD, 2.9 and 0.2% SD, 1.9). Highest rates of annual FVC decline > 10% (21%) and annual fibrosis progression (1.2%) were seen in patients with high CCL18 and early disease (< 3 years). In multivariate analyses, CCL18 was associated with annual FVC decline > 10% (OR, 1.1; 95% CI, 1.01-1.11) and FVC < 70% at follow-up (OR, 3.1; 95% CI, 1.08-8.83). Survival analyses showed that patients with high CCL18 had reduced 5- and 10-year cumulative survival compared with patients with low CCL18 (85% and 74%, compared with 97% and 89%, respectively; P = .001). Conclusions The results from this prospective cohort reinforce the notion that high CCL18 may serve as a marker for early identification of progressive ILD in SSc.
Detection of local tumor progression (LTP) after radiofrequency (RF) ablation of colorectal cancer liver metastases may facilitate repeat intervention with potential benefits for patient survival. ...Ablative margins 1 month after RF ablation may predict LTP, and repeated three-dimensional (3D) volumetric analysis of coagulation volume after ablation may provide earlier detection of LTP versus conventional morphologic criteria.
Seven patients with LTP and four patients without LTP after a follow-up of at least 24 months were identified. Multidetector computed tomography (CT) was performed at 1 and 3 months after RF ablation and then at 3-month intervals until 24 months. Ablative margins were determined from preablation tumor diameter and the corresponding coagulation diameter 1 month after ablation. Postablation coagulation volume was measured from 81 follow-up multidetector CT images using a seeding-based semiautomatic 3D method.
LTP was detected at a median of 9 months (range, 6-21 months) after RF ablation. A coagulation diameter smaller than the preoperative tumor diameter was associated with LTP. Increase in coagulation volume was found in six of seven patients at the time of diagnosis of LTP by conventional morphologic criteria.
Three-dimensional volumetric analysis of postablation coagulation volume is feasible for detection of LTP after RF ablation of colorectal cancer liver metastases. No advantage in early detection of LTP was found for 3D volumetric analysis compared with conventional morphologic criteria in this preliminary study. These findings may reflect a type II error caused by the limited sample size.
Patients with common variable immunodeficiency (CVID) have low serum IgG, IgA, and/or IgM levels and recurrent airway infections. Radiologic pulmonary abnormalities and impaired function are common ...complications. It is unclear to what extent IgG replacement treatment prevents further pulmonary damage and how factors beside infections may contribute to progression of disease.
To study the development of pulmonary damage and determine how clinical and immunologic factors, such as serum IgG, may contribute to possible changes.
In a retrospective, longitudinal study of 54 patients with CVID already treated with immunoglobulins, we examined changes of lung function and findings on high-resolution computed tomography (HRCT), obtained at 2 time points (the date of the last pulmonary function measurement before April 2005 T1 and the date of the measurement performed closest to 5 years earlier T0) 2 to 7 years apart and explored possible relations to clinical and immunologic factors such as levels of IgG, tumor necrosis alpha (TNF-alpha), and mannose-binding lectin (MBL) in serum.
Despite a mean (SD) serum IgG level of 7.6 (2.3) g/L for all the patients during the entire study period, lung function decreased from T0 to T1. The combination of a low serum IgA level and serum MBL was associated with the presence of bronchiectasis and lower lung function and with worsening of several HRCT abnormalities from T0 to T1. Increased serum levels of TNF-alpha were related to deterioration of gas diffusion. A mean serum IgG level less than 5 g/L between T0 and T1 was associated with worsening of linear and/or irregular opacities seen on HRCT.
For a period of 4 years, lung function and HRCT deteriorated in CVID patients treated with immunoglobulins.
